AstraZeneca’s cancer drug disappoints as potential COVID-19 treatment
(Reuters) – AstraZeneca’s blood cancer treatment, Calquence, failed to improve survival rates and prevent lung failure in patients hospitalised with symptoms of COVID-19, the drugmaker said on Thursday, citing results from mid-stage trials.
The company called the outcome “disappointing”. It said its other efforts to combat the pandemic – a possible vaccine developed with Oxford University, and an experimental antibody-based COVID-19 treatment – were not affected.
AstraZeneca is among leading contenders in the race for a working vaccine for the novel coronavirus. Competitor Pfizer Inc this week published efficacy data that were seen as a major milestone on the way to a global immunisation campaign next year.